Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andersson

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Blood|July 30, 2005
Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factorsDeirdre A Hill, Ethel Gilbert, Graça M Dores, et al.
International Journal of Radiation Oncology, Biology, Physics|May 28, 2013
Radiation dose and subsequent risk for stomach cancer in long-term survivors of cervical cancerRuth A Kleinerman, Susan A Smith, Eric Holowaty, et al.
Journal of the National Cancer Institute|October 6, 2005
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphomaLois B Travis, Deirdre Hill, Graça M Dores, et al.
Breast Cancer Research and Treatment|September 5, 2009
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trialEvandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized TrialAmir Sonnenblick, Dominique Agbor-Tarh, Ian Bradbury, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2013
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study reportJonine L Bernstein, Duncan C Thomas, Roy E Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-UpMartine Piccart, Marion Procter, Debora Fumagalli, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Blood|July 30, 2005
Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factorsDeirdre A Hill, Ethel Gilbert, Graça M Dores, et al.
International Journal of Radiation Oncology, Biology, Physics|May 28, 2013
Radiation dose and subsequent risk for stomach cancer in long-term survivors of cervical cancerRuth A Kleinerman, Susan A Smith, Eric Holowaty, et al.
Journal of the National Cancer Institute|October 6, 2005
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphomaLois B Travis, Deirdre Hill, Graça M Dores, et al.
Breast Cancer Research and Treatment|September 5, 2009
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trialEvandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2017
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized TrialAmir Sonnenblick, Dominique Agbor-Tarh, Ian Bradbury, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2013
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study reportJonine L Bernstein, Duncan C Thomas, Roy E Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-UpMartine Piccart, Marion Procter, Debora Fumagalli, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, et al.
Pageof 10